R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of

See also
Status	Clinical Trial	Phase
Completed	`NCT00374309` - Experimental Vaccine for Prevention of Ebola Virus Infection	Phase 1
Completed	`NCT03098862` - PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Completed	`NCT02509494` - Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo	Phase 3
Recruiting	`NCT06093646` - Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda	N/A
Completed	`NCT02495246` - A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV	Phase 1
Completed	`NCT04906629` - INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees	Phase 1
Completed	`NCT05064956` - Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)	Phase 2
Withdrawn	`NCT04268966` - An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola	Phase 2
Completed	`NCT02267109` - Phase 1 Trial of Ebola Vaccine in Mali	Phase 1
Not yet recruiting	`NCT04822376` - Prophylaxis Vaccine Antibodies Ebola	Phase 2
Recruiting	`NCT02333578` - Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment	N/A
Completed	`NCT02662855` - Efficacy of Favipiravir Against Severe Ebola Virus Disease	Phase 2
Active, not recruiting	`NCT04152486` - Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC	Phase 3
Terminated	`NCT04250168` - Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Completed	`NCT03161366` - Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine	Phase 3
Completed	`NCT03140774` - Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
Suspended	`NCT03462004` - Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein	Phase 1
Active, not recruiting	`NCT02876328` - Partnership for Research on Ebola VACcinations	Phase 2
Not yet recruiting	`NCT06126822` - Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC	Phase 3
Not yet recruiting	`NCT05202288` - Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers	Phase 2

NCT number	NCT03576690
Study type	Expanded Access
Source	Regeneron Pharmaceuticals
Contact	Requests for compassionate use must be initiated by a treating p
Phone	844-734-6643
Email	compassionateuserequests@regeneron.com
Status	Available
Phase

R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms